ABT
Abbott Laboratories
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
USD 107.81
Buy <=wait / entry
USD 98.00
Trim >=take some off
USD 118.00
Thesis breakA material cybersecurity incident causing operational or regulatory disruption, ...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 29% | 100 / 100 | 29.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 21% | 10 / 100 | 2.1 |
| Weighted conviction | 62 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- Completed acquisition of Exact Sciences on March 23, 2026, establishing leadership in oncology diagnostics market
- Q1 2026 results with 7.8% reported sales growth, adjusted diluted EPS $1.15 (up 6%), and updated full-year 2026 guidance of 6.5-7.5% comparable sales growth and $5.38-$5.58 adjusted EPS including $0.20 acquisition dilution
- Q2 2026 earnings conference call scheduled for July 16, 2026, with reported adjusted EPS of $1.31 beating estimates of $1.29